Focused On-demand Library for Large ribosomal subunit protein eL18

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q07020

UPID:

RL18_HUMAN

Alternative names:

60S ribosomal protein L18

Alternative UPACC:

Q07020; F8VWC5; Q8WTZ6

Background:

The Large ribosomal subunit protein eL18, also known as 60S ribosomal protein L18, plays a crucial role in protein synthesis. As a component of the large ribosomal subunit, it is pivotal in the translation process, facilitating the assembly of amino acids into protein chains. This protein's involvement in the ribosome's structure and function underscores its importance in cellular biology.

Therapeutic significance:

Given its association with Diamond-Blackfan anemia 18, a condition marked by congenital non-regenerative hypoplastic anemia, the study of Large ribosomal subunit protein eL18 holds therapeutic promise. Understanding the role of Large ribosomal subunit protein eL18 could open doors to potential therapeutic strategies for this and related disorders.